Newborn screening for X-linked adrenoleukodystrophy: Further evidence high throughput screening is feasible

Christiane Theda; Katy Gibbons; Todd E. DeFor; Pamela K. Donohue; W. Christopher Golden; Antonie D. Kline; Fizza Gulamali-Majid; Susan R. Panny; Walter C. Hubbard; Richard O. Jones; Anita K. Liu; Ann B. Moser; Gerald V. Raymond

doi:10.1016/j.ymgme.2013.10.019

Newborn screening for X-linked adrenoleukodystrophy: Further evidence high throughput screening is feasible

Christiane Theda
, Katy Gibbons
, Todd E. DeFor
, Pamela K. Donohue
, W. Christopher Golden
, Antonie D. Kline
, Fizza Gulamali-Majid
, Susan R. Panny
, Walter C. Hubbard
, Richard O. Jones
, Anita K. Liu
, Ann B. Moser
, Gerald V. Raymond

Department of Pediatrics

Research output: Contribution to journal › Article › peer-review

48 Scopus citations

Abstract

X-linked adrenoleukodystrophy (ALD) is characterized by adrenal insufficiency and neurologic involvement with onset at variable ages. Plasma very long chain fatty acids are elevated in ALD; even in asymptomatic patients. We demonstrated previously that liquid chromatography tandem mass spectrometry measuring C26:0 lysophosphatidylcholine reliably identifies affected males. We prospectively applied this method to 4689 newborn blood spot samples; no false positives were observed. We show that high throughput neonatal screening for ALD is methodologically feasible.

Original language	English (US)
Pages (from-to)	55-57
Number of pages	3
Journal	Molecular Genetics and Metabolism
Volume	111
Issue number	1
DOIs	https://doi.org/10.1016/j.ymgme.2013.10.019
State	Published - 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Biology
Genetics
Endocrinology

Access to Document

10.1016/j.ymgme.2013.10.019

Cite this

Theda, C., Gibbons, K., DeFor, T. E., Donohue, P. K., Golden, W. C., Kline, A. D., Gulamali-Majid, F., Panny, S. R., Hubbard, W. C., Jones, R. O., Liu, A. K., Moser, A. B., & Raymond, G. V. (2014). Newborn screening for X-linked adrenoleukodystrophy: Further evidence high throughput screening is feasible. Molecular Genetics and Metabolism, 111(1), 55-57. https://doi.org/10.1016/j.ymgme.2013.10.019

@article{6f7ce33cf25349589c21f71a13665bee,

title = "Newborn screening for X-linked adrenoleukodystrophy: Further evidence high throughput screening is feasible",

abstract = "X-linked adrenoleukodystrophy (ALD) is characterized by adrenal insufficiency and neurologic involvement with onset at variable ages. Plasma very long chain fatty acids are elevated in ALD; even in asymptomatic patients. We demonstrated previously that liquid chromatography tandem mass spectrometry measuring C26:0 lysophosphatidylcholine reliably identifies affected males. We prospectively applied this method to 4689 newborn blood spot samples; no false positives were observed. We show that high throughput neonatal screening for ALD is methodologically feasible.",

author = "Christiane Theda and Katy Gibbons and DeFor, \{Todd E.\} and Donohue, \{Pamela K.\} and Golden, \{W. Christopher\} and Kline, \{Antonie D.\} and Fizza Gulamali-Majid and Panny, \{Susan R.\} and Hubbard, \{Walter C.\} and Jones, \{Richard O.\} and Liu, \{Anita K.\} and Moser, \{Ann B.\} and Raymond, \{Gerald V.\}",

note = "Funding Information: Supported by a grant from the NICHD ( R01HD057136 ), European Leukodystrophy Association , Kelly Foundation , Run for ALD (Kane Family) , United Leukodystrophy Foundation , and the Myelin Project . The AB Sciex API4000 triple quadrupole mass spectrometer (SN J3270205) was purchased with proceeds of NIH Grant 1S10 RR16798 awarded to Walter C. Hubbard. ",

year = "2014",

doi = "10.1016/j.ymgme.2013.10.019",

language = "English (US)",

volume = "111",

pages = "55--57",

journal = "Molecular Genetics and Metabolism",

issn = "1096-7192",

publisher = "Academic Press Inc.",

number = "1",

}

Theda, C, Gibbons, K, DeFor, TE, Donohue, PK, Golden, WC, Kline, AD, Gulamali-Majid, F, Panny, SR, Hubbard, WC, Jones, RO, Liu, AK, Moser, AB & Raymond, GV 2014, 'Newborn screening for X-linked adrenoleukodystrophy: Further evidence high throughput screening is feasible', Molecular Genetics and Metabolism, vol. 111, no. 1, pp. 55-57. https://doi.org/10.1016/j.ymgme.2013.10.019

TY - JOUR

T1 - Newborn screening for X-linked adrenoleukodystrophy

T2 - Further evidence high throughput screening is feasible

AU - Theda, Christiane

AU - Gibbons, Katy

AU - DeFor, Todd E.

AU - Donohue, Pamela K.

AU - Golden, W. Christopher

AU - Kline, Antonie D.

AU - Gulamali-Majid, Fizza

AU - Panny, Susan R.

AU - Hubbard, Walter C.

AU - Jones, Richard O.

AU - Liu, Anita K.

AU - Moser, Ann B.

AU - Raymond, Gerald V.

N1 - Funding Information: Supported by a grant from the NICHD ( R01HD057136 ), European Leukodystrophy Association , Kelly Foundation , Run for ALD (Kane Family) , United Leukodystrophy Foundation , and the Myelin Project . The AB Sciex API4000 triple quadrupole mass spectrometer (SN J3270205) was purchased with proceeds of NIH Grant 1S10 RR16798 awarded to Walter C. Hubbard.

PY - 2014

Y1 - 2014

N2 - X-linked adrenoleukodystrophy (ALD) is characterized by adrenal insufficiency and neurologic involvement with onset at variable ages. Plasma very long chain fatty acids are elevated in ALD; even in asymptomatic patients. We demonstrated previously that liquid chromatography tandem mass spectrometry measuring C26:0 lysophosphatidylcholine reliably identifies affected males. We prospectively applied this method to 4689 newborn blood spot samples; no false positives were observed. We show that high throughput neonatal screening for ALD is methodologically feasible.

AB - X-linked adrenoleukodystrophy (ALD) is characterized by adrenal insufficiency and neurologic involvement with onset at variable ages. Plasma very long chain fatty acids are elevated in ALD; even in asymptomatic patients. We demonstrated previously that liquid chromatography tandem mass spectrometry measuring C26:0 lysophosphatidylcholine reliably identifies affected males. We prospectively applied this method to 4689 newborn blood spot samples; no false positives were observed. We show that high throughput neonatal screening for ALD is methodologically feasible.

UR - https://www.scopus.com/pages/publications/84891825729

UR - https://www.scopus.com/pages/publications/84891825729#tab=citedBy

U2 - 10.1016/j.ymgme.2013.10.019

DO - 10.1016/j.ymgme.2013.10.019

M3 - Article

C2 - 24268529

AN - SCOPUS:84891825729

SN - 1096-7192

VL - 111

SP - 55

EP - 57

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

IS - 1

ER -

Newborn screening for X-linked adrenoleukodystrophy: Further evidence high throughput screening is feasible

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this